Introduction Ibrutinib is a groundbreaking medication used to treat various blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. Developed as a targeted therapy, Ibrutinib has transformed the treatment landscape for these conditions by selectively inhibiting Bruton's tyrosine kinase (BTK), a critical component in...